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a b s t r a c t
Acceptance and Commitment Therapy (ACT) is a theoretically coherent approach addressing common
processes across a range of disorders. The aim of this study was to investigate the effectiveness of a
group-based ACT intervention for “treatment-resistant” participants with various diagnoses, who had
already completed at least one psychosocial intervention. Of 61 individuals randomized into a service-
based trial comparing ACT and Treatment as Usual based on Cognitive Behavior Therapy (TAU-CBT), 45
provided data (ACT n¼26; TAU-CBT n¼19). Primary outcomes were measures of psychological
symptoms. All participants showed reduced symptoms immediately after intervention but improve-
ments were more completely sustained in the ACT group at 6-month follow-up. More elaborate and
more fully controlled evaluations are required to conﬁrm the ﬁndings, improve understanding of ACT
processes and assess health economic beneﬁts.
& 2014 Published by Elsevier Inc. on behalf of Association for Contextual Behavioral Science.
1. Introduction
Despite considerable advances in psychotherapy for individuals
struggling with acute psychological disorders, numerous outcome
studies indicate that a substantial proportion of clients respond
poorly, even to well-validated interventions. For example, between
30 and 60% of clients fail to make clinically meaningful improve-
ments following Cognitive Behavioral Therapy (CBT), Interpersonal
Therapy, or Psychodynamic Therapy across a range of difﬁculties,
including Generalized Anxiety Disorder (Borkovec, Newman, Pincus,
& Lytle, 2002), Bulimia Nervosa (Agras, Walsh, Fairburn, Wilson, &
Kraemer, 2000; Wilson, Fairburn, & Agras, 1997) Anorexia Nervosa
(Dare, Eisler, Russell, Treasure, & Dodge, 2001), and Depression
(DeRubeis et al., 2005; Dimidjian et al., 2006; Elkin et al., 1989;
Leichsenring, 2001). CBT has been shown to be relatively ineffective
in treating depression when clients present with more chronic, co-
morbid, and personality disordered symptoms (Fournier et al., 2008).
Clients with these multi-diagnostic presentations may also be
categorized as “treatment-resistant” if they meet certain criteria
for relapse or chronicity. For example, Kenny and Williams (2007)
deﬁned treatment resistance in relation to depression as having
had three or more previous episodes, or one chronic episode
lasting 1 year or more. Such clients consume a disproportionate
amount of clinical resources (Amsterdam, Hornig, & Nierenberg,
2001; Crown et al., 2002; Russell et al., 2004) but, ironically, they
are sometimes excluded from clinical trials to reduce variability
and thus increase internal validity (Persons & Silberschatz, 1998;
Westen, Novotny, & Thompson-Brenner, 2004; Zarin, Young, &
West, 2005).
Fortunately, there is some evidence that “third wave” (Hayes,
2004) forms of behavior therapy incorporating principles of mind-
fulness can successfully treat complex and intransigent clinical
problems such as chronic or recurrent depression and personality
disorder (e.g., Lynch, Trost, Salsman, & Linehan, 2007; Ma &
Teasdale, 2004; Segal, Williams & Teasdale, 2002). Acceptance
and Commitment Therapy (ACT; Hayes, Strosahl & Wilson, 1999)
has ﬁgured prominently amongst these new forms. ACT's central
focus, distinguishing it from other psychotherapies, is the notion
that a broad range of psychological difﬁculties, typically viewed as
distinct under DSM-IV, emerges from our capacity for human
language (Hayes et al., 2004a; Wilson, Hayes, Gregg, & Zettle,
2001). ACT uses several therapeutic techniques to increase
psychological ﬂexibility by undermining unhelpful verbal repre-
sentations of experience, encouraging a present moment focus,
and promoting action consistent with long-term values (Hayes,
Luoma, Bond, Masuda, & Lillis, 2006). Because ACT aims to teach
generic positive psychological skills, rather than targeting speciﬁc
unwanted experiences and feelings (Lundgren, Dahl, & Hayes,
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2008), it is inherently transdiagnostic (Hayes et al., 2006). The
central role that ACT accords to values may facilitate motivation in
treatment-resistant clients with long-standing problems. This shift
in focus may be especially salient to clients more familiar with
forms of therapy that emphasize symptomatic relief.
Following Hayes et al. (2006), some recent studies have
attempted to evaluate ACT with heterogeneous client groups. For
example, Fledderus, Bohlmeijer, Pieterse, and Schreurs (2012)
compared two versions of an ACT self-help intervention (minimal
vs. substantive email support) with a waiting list control, using a
sample of individuals experiencing depression and/or anxiety.
Improvements in each experimental condition exceeded those
for controls, and were sustained at 3 month follow-up. Forman,
Herbert, Moitra, Yeomans, and Geller (2007) also compared ACT
with Cognitive Therapy for individuals with severe anxiety and/or
depression. They kept their “exclusion criteria purposefully broad
for maximum external validity” (p. 8). Both groups improved on a
range of measures, but the mechanisms of action appeared to
differ in ways consistent with the underlying therapeutic models.
Finally, Lang et al. (2012) have described a protocol for an ongoing
randomized controlled trial designed to compare ACT with
psychotherapy for military veterans exhibiting high levels of
comorbidity.
We recently conducted a treatment development trial to test
the utility of ACT with a heterogeneous group of clients in a
naturalistic clinical setting (Clarke, Kingston, Wilson, Bolderston, &
Remington, 2012). Ten participants presented: All had clinical
disorders (Axis I diagnoses), and half met criteria for co-morbid
personality disorders (Axis II diagnoses). The inclusion criteria
speciﬁed that participants had “already received at least one
previous episode of therapy, for which they attended at least eight
sessions, and … were being re-referred with signiﬁcant residual
mental health concerns” (p. 562; emphasis in the original). This
criterion for treatment resistance differs from that of Kenny and
Williams (2007) because (a) it is not speciﬁc to depression, and
(b) it requires the client to have had psychological treatment.
In fact, group members had on average attended a mean of
3.5 previous psychological interventions. After 16 ACT-based group
sessions using a protocol adapted from Hayes and Smith (2005),
the group showed signiﬁcant improvements in self-reported
depression, overall symptomatology and quality of life, with
medium to large effect sizes on all measures. Individual analyses
showed clinically signiﬁcant and reliable change in up to 70% of
participants. Moreover, signiﬁcant improvements over baseline
were maintained at 6 and 12 month follow-up. These ﬁndings,
although promising, are tentative because the study was uncon-
trolled and the small sample of clients limited the power to detect
differences. To increase external validity, replication using a
randomized controlled trial (RCT) design is required.
Thus, building on previous research, the aim of the present
study was to assess the effectiveness of ACT for a heterogeneous
group of treatment-resistant clients. Following the recommenda-
tions of Smout, Hayes, Atkins, Klausen, and Duguid (2012), we
used an active CBT-based control group for comparison purposes.
We designated this control condition as Treatment as Usual based
on CB (TAU-CBTT) because CBT is the most widely utilized and
researched psychotherapy (Norcross, Hedges, & Castle, 2002).
Although most CBT research is disorder-speciﬁc, the use of uniﬁed
treatment protocols for mood and anxiety disorders is now being
explored by some investigators (McEvoy, Nathan, & Norton, 2009).
CBT-based TAU was therefore considered an appropriate active
comparison condition against which to evaluate ACT.
In keeping with previous ACT research, we chose to conduct a
small-scale RCT utilizing a pragmatically acquired sample. We
chose our primary outcome measures to reﬂect the heterogeneous
and treatment-resistant characteristics of this sample, and the
goals of ACT-based intervention. Because our selection criterion
did not specify any diagnosis, we assessed participants' overall
symptomatology. Because treatment resistance is strongly asso-
ciated with depression (Blom et al., 2007; Fournier et al., 2009;
Joyce et al., 2002; Sotsky et al., 1991), we used a robust measure
of depressive symptomatology. Our secondary outcome measures
were chosen to monitor changes in complex personality dis-
order symptomatology and quality of life; the latter is a non-
symptomatic measure expected to vary with personal adjustment.
Assessments were made post-therapy and at 6 month follow-up,
to assess whether any beneﬁts had been sustained. Furthermore,
because inappropriate care can worsen symptoms and personality
pathology for treatment-resistant clients (Clarke, Thomas, &
James, 2013; Tyrer & Simmonds, 2003), we assessed changes in
participant functioning on both an individual and a group basis.
We further assessed preliminary theory-driven process variables
for both conditions.
We hypothesized that participants receiving ACT would show
greater improvements in primary outcome measures across time
than those receiving TAU-CBT-. We also predicted that a greater
proportion of ACT participants would improve and that less would
deteriorate than CBT-based TAU participants.
2. Method
2.1. Design
We used an RCT to compare the effectiveness of a 16 week,
group-based ACT intervention with a group-based TAU-CBT inter-
vention of the same duration at a specialist personality disorder
clinic in a public health setting (ISRCTN17801606). The Dorset
Research and Development Support Unit assigned participants to
treatments using block randomization (block sizes 2–4) to ensure
the numbers allocated to each intervention were always closely
balanced. Outcome and process measures were obtained at base-
line, post-therapy and follow-up. The protocol was approved
by the UK National Health Service Research Ethics Committee
(Dorset: 06/Q2201/170).
2.2. Participants
Participants were recruited from referrals to a Community
Mental Health Team and a specialist outpatient service for people
with a personality disorder. Consistent with our earlier deﬁnition
of treatment resistance (Clarke et al., 2012), eligible participants
had received at least one previous 8-session episode of psycholo-
gical therapy and had been re-referred. No independent data were
available on the quality or ﬁdelity of previous treatments. Owing
to the group-based nature of the intervention, and the relative
vulnerability of the client group, exclusion criteria (based on
DSM-IV, 1994), were intellectual disability, schizophrenia or other
psychotic illness, or any of the following high risk behaviors:
(a) current drug or alcohol dependency; (b) a current eating
disorder and a BMI of o16; and (c) deliberate self-harm in the
past 6 months (deﬁned using Kreitman's (1977) criteria). In
keeping with the service protocol, clients who engaged in self-
harming behavior monthly or more were referred directly to an
established Dialectical Behavior Therapy program.
2.3. Measures
2.3.1. Primary outcome measures
The Symptom Check List-90 Revised (SCL-90-R; Derogatis, 1993),
a 90-item self-report measure, was used to measure psychiatric
distress. Given the symptomatic heterogeneity of the conditions, we
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used the Global Severity Index to evaluate a broad range of
psychological problems and symptoms of psychopathology, provid-
ing scores on nine primary symptom dimensions and three global
indices. A higher GSI score indicates greater psychiatric distress.
Internal consistency and test–retest reliability for the GSI are
excellent (α¼ .90, r¼ .91, respectively; Derogatis, 1993; Derogatis &
Spencer, 1982). We used the Beck Depression Inventory-II (BDI-II;
Beck, Steer, & Brown, 1996b) to assess depression: Higher scores
indicate greater depressive severity. Internal consistency and test–
retest reliability are excellent for this measure (α¼ .91, r¼ .93,
respectively; Beck, Steer, Ball & Ranieri, 1996a; Beck et al., 1996b).
2.3.2. Secondary outcome measures
We used the Structured Clinical Interview for DSM-IV Axis II
Disorders (SCID-II; First, Gibbon, Spitzer, & Williams, 1996) to
assess symptomatology of 10 personality disorders. This measure
has good to excellent interrater reliability (Lobbestael, Leurgans,
& Arntz, 2011), and acceptable to good internal consistency and
test–retest reliability (α¼ .71–.94, kappa¼ .61–.68; Maffei et al.,
1997; Williams et al., 1992; respectively). The SCID was used to
index “presence” (symptoms reach diagnostic threshold) versus
“absence” (symptoms, if present, do not reach diagnostic thresh-
old) of a personality disorder diagnosis. We used the World Health
Organization Quality of Life (WHOQOL; Skevington, Lotfy, &
O’Connell, 2004) to assess quality of life across four domains
(physical health, psychological health, social relationships, and
environment). Higher scores indicate higher quality of life. This
measure has acceptable to good internal consistency and test–
retest reliability (α¼ .55–.87, r¼ .71–.91, respectively; Skevington
et al., 2004; Taylor, Myers, Simpson, McPherson, & Weatherall,
2004).
2.3.3. Process measures
We used the Acceptance and Action Questionnaire (AAQ,
9-item; Hayes et al., 2004a), a measure designed to examine
ACT-theory consistent changes in psychological ﬂexibility during
treatment, with higher scores indicating less ﬂexibility. Internal
consistency and test–retest reliability are adequate for this mea-
sure (α¼ .77, r¼ .64, respectively; Hayes et al., 2004a). The 15-item
Mindful Attention Awareness Scale (MAAS; Brown & Ryan, 2003)
was selected to assess the frequency of mindful states, with higher
scores indicating greater mindfulness. Internal consistency and
test–retest reliability are good for this measure (α¼ .86, r¼ .81,
respectively; Brown & Ryan, 2003). Finally, we used the Automatic
Thoughts Questionnaire/Thought Believability and Frequency
(ATQ/TBTF; Bach & Hayes, 2002), a modiﬁed version of the 30-
item intrusive thoughts measure, to assess thought believability
and frequency. Using a 5-point scale, participants rated how
frequently they had experienced unwanted/intrusive thoughts
and emotions in the past week, and how believable and meaningful
these experiences were. Internal consistency and test–retest
reliability data are not available for this measure.
2.3.4. Treatment integrity measure
In keeping with previous research (Forman et al., 2007), the
Drexel University CT/ACT Therapist Adherence and Competence
Rating Scale (DUACRS) was used to rate treatment integrity in both
conditions. The scale comprises six subscales: ACT-Speciﬁc Behavior;
CBT-Speciﬁc Behavior; and four generic measures (Therapist Compe-
tence; Relationship-Building; Treatment Implementation; Miscella-
neous Therapist Behaviors). Reported inter-reliability (intra-class
correlation coefﬁcient¼ .95) and internal consistency (α¼ .92) are
excellent (Forman et al., 2007).
2.4. Interventions
Participants in both conditions attended weekly sessions lasting
2 h, with a 10 min break and ending with a homework task.
Although neither treatment was fully manualized, the content of
each closely followed client-oriented self-help manuals (Greenberg &
Padesky, 1995; Hayes & Smith, 2005).
2.4.1. Acceptance and Commitment Therapy
ACT groups were run by a consultant clinical psychologist and a
clinical psychologist (mean post-qualiﬁcation experience¼19
years). Both were ACT-trained and under supervision of an ACT
originator (Dr. Kelly Wilson). All sessions began with a brief
mindfulness exercise and a homework review. The remainder of
the time was spent in didactic and experiential learning using
pre-planned materials and exercises. These were chosen to enable
clients to both understand ACT processes and perspectives and to
experience their impact. Each session addressed a speciﬁc theme
taken from Hayes and Smith (2005): These included experiential
avoidance, cognitive fusion, willingness, and values. Homework
was set at the end of each session, often in the form of behavioral
practices and experiments. Despite the structured nature of the
intervention, the therapists made in-the-moment decisions with
regard to the intensity with which particular topics were explored.
A more detailed account of the intervention appears in Clarke et al.
(2012).
2.4.2. Treatment-as-usual based on Cognitive Behavior Therapy
TAU-CBT groups were run by either a clinical psychologist and a
counselor (mean post-qualiﬁcation experience¼9 years), or by a
nurse specialist in CBT and a counselor (mean post-qualiﬁcation
experience¼18 years). All TAU-CBT therapists were CBT-trained
and under the supervision of the local service lead CBT practi-
tioner (19 years post-qualiﬁcation experience). TAU-CBT contained
no mindfulness components. Early sessions introduced the model.
Later sessions reviewed participants' negative automatic thoughts
and thinking biases, identiﬁed their core schemas and discussed
the relationship between early experiences and long-standing
beliefs. CBT skills, such as challenging thoughts and conducting
behavioral experiments, were taught. The ﬁnal sessions focused on
relapse prevention.
2.5. Procedure
On referral, clients meeting inclusion and exclusion criteria
were sent a letter informing them about the trial and inviting
them to an assessment session. Those that attended and gave
written informed consent were then screened before completing
all baseline measures. A SCID-II was used to assess personality
disorder symptomatology. This was administered by one of two
postgraduate level psychologists, a psychiatrist, or a clinical
psychologist, all of whom were trained to a level of 80% con-
cordance with other SCID-II-trained clinicians. Consistent with
previous research (e.g., Clarke et al., 2012; Emmelkamp, Benner,
Kuipers, Feiertag, & Koster, 2006) participants were asked to
report symptoms since early adolescence (diagnostic criterion)
and in the last year (symptomatic criterion). Details of previous
treatment episodes were also obtained and subsequently veriﬁed
from NHS clinical ﬁles. When baseline data had been obtained,
participants were randomly assigned to conditions. Three groups
were run in each condition, with a maximum of 11 participants
per group.
Psychometric assessment to obtain process and outcome data
was repeated 1–3 weeks after therapy termination (post-therapy)
and again at 6-month follow-up. At follow-up, a post-intervention
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SCID-II was administered to assess symptoms in the interval since
baseline assessment (symptomatic criterion).
2.5.1. SCID reliability
All SCID-II interviews were audio-taped and a random sample
(25%) was rated by three experienced independent assessors
(a clinical psychologist and two psychiatrists), who were naive to
the treatment allocation. Inter-rater reliability for “PD present
versus absent” was high (kappa¼ .84; 95% agreement).
2.5.2. Treatment integrity
At the end of the study, an independent assessor (a psychiatrist
with specialist interest in psychotherapy including ACT and CBT)
rated audio-recordings of a randomly selected 15% of ACT and
TAU-CBT group sessions using the DUACRS. Half of these sessions
were then rated by another independent assessor (a CBT- and
ACT-trained consultant clinical psychologist). Both raters were
able successfully to differentiate the treatment conditions for all
sessions coded. Therapists spent an average of 68.2% of sessions on
treatment-speciﬁc components and only 3.4% on components
speciﬁc to the non-assigned condition. Inter-rater reliability across
the ﬁve relevant adherence sub-scales was acceptable (kappa¼ .62,
range .50–.78). Therapist competence was judged to be “good”,
“very good”, or “excellent” for 78.6% of rated sessions. Data from
both raters indicated that there was no signiﬁcant difference
between ACT and TAU-CBT sessions in terms of score on the
relationship-building subscale of the DUACRS (Rater 1: U¼14.00,
p¼ .21; Rater 2: U¼8.00, p¼1.00).
2.6. Overview of statistical methods
To assess group change, a series of mixed-design Analyses of
Variance (ANOVA) was used to establish the impact of treatment
on all outcome and process measures. Further analyses were
conducted with post hoc repeated measures ANOVA. Separate
analyses were based on (a) data from participants who completed
treatment and provided follow-up data; that is, on treatment
administered basis; and (b) data from all recruited participants
who completed pre- and post-assessments, regardless of whether
they completed treatment (i.e., intention-to-treat; Ost, 2008).
Intention-to-treat analyses assessed group change on a more
conservative basis. Like previous trials with relatively small sample
sizes (Morton, Snowdon, Gopold, & Guymer, 2012), Cohen's d
between-group effect sizes were calculated by dividing the mean
differences by the baseline pooled standard deviations (Cohen,
1988), even when no signiﬁcant group effects had been obtained
at post-test. Using Cohen's (1988) guidelines, the following con-
ventions were used: “small” (d¼ .2), “medium” (d¼ .5) and “large”
(d¼ .8).
Because the SCID-II is a nominal variable, the data were
dichotomized into two categories (“personality disorder” or “no
personality disorder”) and the Fisher's Exact Test was used to
compare the distribution of scores between the two study groups.
We used Jacobson and Truax's (1991) criteria for reliable and
clinically signiﬁcant change to assess whether group differences
were reﬂected in outcomes for individual participants. Statistics
were computed for changes (a) between baseline and post-therapy
and (b) between baseline and follow-up, using the published
normative values for the GSI and BDI-II and test–retest reliability
values stated in Section 2.
Finally, analyses assessing whether changes in theoretically
relevant process measures during treatment predicted outcomes
at follow-up were conducted to explore ACT theory-consistent
processes of change. Separate multiple regressions for ACT and
TAU-CBT were computed using residual gain scores (Steketee &
Chambless, 1992 1) to index pre- to post-therapy change, adjusted
for repeated testing.
3. Results
3.1. Participant recruitment
Fig. 1 shows the participant ﬂow throughout the trial. Of 140
participants assessed for eligibility, 50 did not respond to the
written invitation. Of the remaining 90, 25 did not, on closer
examination, meet the inclusion criteria, two met the exclusion
criteria (eating disorder and deliberate self-harm), and two were
excluded for other reasons (e.g. left the area). This yielded a
sample size of 61 participants randomized between the two
conditions (ACT: n¼30; TAU-CBT: n¼31), a ﬁgure compatible with
that reported in previous ACT research involving participants with
complex problems (Gratz & Gunderson, 2006; Hayes et al., 2004b).
3.2. Baseline data
The ﬁnal sample consisted of 41 women (67.21%) and 20 men,
with a mean age of 43.46 (s.d.¼12.35). Table 1 provides demo-
graphic information on the full sample, and baseline psychometric
data. Clinical norms for the GSI indicated that 44 participants (72%)
had psychiatric symptoms within the clinical range and 45 (76% of
those who returned their questionnaires) were experiencing mod-
erate to severe levels of depression, as assessed with the BDI-II.
Other diagnoses included anxiety disorders (e.g. agoraphobia and
social phobia), eating disorders (e.g. bulimia), and adjustment
disorders. Participants also presented with a range of personality
disorders: 31 (51%) met criteria for at least one personality disorder
and 19 (31%) met criteria for two or more co-morbid disorders. A
broad range of personality disorders were represented, with the
exception of schizoid, schizotypal, and histrionic. A third of parti-
cipants met the diagnostic criteria for depressive personality dis-
order. Avoidant, obsessive-compulsive, paranoid and borderline
personality disorders were each seen in 20–30% of the sample.
There were no signiﬁcant between-group differences on demo-
graphic or baseline characteristics.
3.3. Attrition
Fig. 1 shows that between the baseline and post-therapy
assessments, 12 participants (39%) dropped out of the TAU-CBT
group (ﬁve did not attend any sessions and seven dropped out
during treatment); and four started but discontinued in the ACT
group (13%). A further two participants from the TAU-CBT group
and one participant from the ACT group dropped out between the
post-therapy and follow-up assessments. Ten of the 16 partici-
pants (63%) who discontinued treatment met diagnostic and
symptomatic criteria for a personality disorder. Because differ-
ences in attrition between conditions during active therapy were
signiﬁcant (χ²¼5.074, p¼ .024), comparisons of completers' versus
non-completers' baseline data were conducted. These indicated
that non-completers had higher baseline GSI scores (t(59)¼1.926,
p¼ .059) and lower WHOQOL scores (t(59)¼2.531, p¼ .014).
3.4. Outcomes
Descriptive analyses conﬁrmed that the data for all continuous
study variables were normally distributed.
1 The residual gain score was computed by standardizing pre- and post-
treatment means and subtracts the T1 score, multiplied by the correlation between
T1 and T2 scores, from T2 (i.e., RG¼ZT2(ZT1 rT1,T2)).
S. Clarke et al. / Journal of Contextual Behavioral Science 3 (2014) 179–188182
3.4.1. Analysis of participants who completed treatment
3.4.1.1. Primary outcome measures. Table 2 shows that groups did
not differ signiﬁcantly in terms of the two primary outcome
measures, but that there were signiﬁcant overall improvements
over time on both measures. Post hoc analyses (adjusted po .01)
revealed signiﬁcant reductions in scores from baseline to post-
therapy (GSI: F(1, 40)¼9.096, p¼ .004; BDI-II: F(1, 38)¼37.128,
po .001) and baseline to follow-up (GSI: F(1, 41)¼16.115, po .001;
BDI-II: F(1,39)¼27.049, po .001).
Examination of means (see Fig. 2) suggested a differential effect
of the two interventions on general symptom severity and depres-
sion. The GroupTime interaction for GSI was not signiﬁcant,
however Fig. 2 shows that GSI scores followed a similar pattern to
the BDI-II scores. For BDI-II scores, a signiﬁcant Group Time
Fig. 1. CONSORT ﬂow chart of patient recruitment to the trial. ACT, acceptance and commitment therapy; TAU-CBT, treatment-as-usual based on cognitive behavioural
therapy.
Table 1
Means (s.d.) of demographic characteristics, and baseline outcome and process measures as a function of group.
Measures ACT TAU-CBT
n Mean (s.d.) n Mean (s.d.)
Age 30 44.03 (12.22) 31 42.90 (12.65)
Gender (% female) 30 73.3 31 61.3
Currently employed/in education (%) 26 42.3 29 51.7
Medication (%) 28 89.3 29 79.3
Previous no. therapeutic episodes 30 2.70 30 3.09
Previous no. sessions 30 59.40 30 45.91
Clinical GSI (%)a 30 73.3 31 71.0
Moderate-severe Depression (%) 29 86.2 30 66.7
PD lifetime criteria (%) 30 53.3 31 48.4
Outcome
GSI 30 1.61 (.60) 31 1.73 (.82)
BDI-II 29 29.62 (10.36) 30 29.83 (13.90)
WHOQOL 30 76.43 (9.22) 31 73.29 (14.74)
Process
AAQ 27 43.77 (7.31) 24 42.01 (6.86)
MAAS 30 51.10 (10.86) 31 50.90 (15.30)
ATQ-TB 30 95.33 (24.95) 30 100.43 (34.03)
ATQ-TF 30 95.70 (26.62) 31 98.00 (32.83)
Note: BDI-II, Beck's Depression Inventory; GSI, Global Severity Index; WHOQOL, Quality of Life; AAQ, Acceptance and Action Questionnaire; MAAS, Mindfulness Attention and
Awareness Scale; ATQ-TB, Automatic Thoughts Questionnaire – Thought Believability; ATQ-TF, Automatic Thoughts Questionnaire – Thought Frequency.
a Percentage of patients who scored on or above the mean psychiatric outpatient norms for the GSI.
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interaction (F(2, 74)¼3.675, p¼ .030) was found. Post hoc analysis
showed this came about because, whereas both groups showed
signiﬁcant reductions between baseline and post-therapy (ACT: F(1,
23)¼29.265, po .001; TAU-CBT: F(1, 14)¼9.441, p¼ .008), only the
ACT group showed a signiﬁcant reduction in BDI-II scores between
baseline and follow-up (ACT: F(1, 23)¼29.817, po .001; TAU-CBT:
F(1, 15)¼3.240, p¼ .092). The medium effect size values obtained for
GSI (d¼ .39) and BDI-II (d¼ .54) at post-therapy reﬂected mean
between-group differences favoring ACT. At follow-up, group differ-
ences again favoring ACT were reﬂected in a medium effect size for
GSI (d¼ .51) and a large effect size for BDI-II (d¼ .90). Although the
Group Time interaction was not signiﬁcant for GSI scores, the
magnitude of the effect size provided a rationale for conducting
post hoc analyses. For ACT participants, these revealed signiﬁcant
GSI reductions from baseline to post-therapy (F(1, 24)¼8.308,
p¼ .008) and baseline to follow-up (F(1, 24)¼19.533, po .001);
the corresponding analyses for TAU-CBT were not signiﬁcant
(adjusted p4 .01).
3.4.1.2. Secondary outcome measures. Twelve participants completing
the ACT group and seven participants completing the TAU-CBT group
met SCID-II diagnostic and symptomatic criteria for at least one
personality disorder at baseline. Of those who received ACT, eight no
longer met symptomatic criteria at follow-up, three remained
symptomatic and one did not complete the full SCID-II assessment.
Of those who received TAU-CBT, three no longer met symptomatic
criteria at follow-up, three continued to be symptomatic and one
dropped out before assessment. These between group differences
were not signiﬁcant (Fisher's Exact Test: p¼ .339).
Analyses showed a signiﬁcant time effect for the WHOQOL,
but no between-group differences (Table 2). Post hoc analyses
(adjusted po .01) revealed a signiﬁcant increase in WHOQOL
scores from baseline to post-therapy (F(1, 38)¼19.195, po .001)
and baseline to follow-up (F(1, 38)¼18.964, po .001). Between-
group comparisons of WHOQOL scores yielded small effect sizes,
favoring TAU-CBT at post-therapy (d¼ .13) and ACT at follow-up
(d¼ .33).
3.4.1.3. Intention-to-treat analysis. Because attrition was selective,
ANOVAs were re-run on an intention-to-treat basis, meaning that
comparisons included all clients who consented to the trial,
regardless of amount of treatment received. Missing data was
managed using the last observation carried forward method
(Spokas, Rodebaugh, & Heinberg, 2008). The results of these
analyses were akin to those for treatment completers. No group
differences were observed but signiﬁcant effects of time were
Table 2
Mean (s.d.) and mixed-design ANOVA for outcome and process measures comparing baseline, post-therapy and follow-up measures (treatment completers).
Measure Completing participants Mixed-design ANOVA
ACT TAU-CBT Time Group TimeGroup
Baseline Post-therapy Follow-up Baseline Post-therapy Follow-up
n M (s.d.) M (s.d.) M (s.d.) n M (s.d.) M (s.d.) M (s.d.) F F F
Outcome
GSI 25 1.55 (.58) 1.12 (.77) .93 (.58) 16 1.47 (.73) 1.30 (.72) 1.19 (.91) 9.574nnn .409 1.407
BDI-II 24 29.58 (9.58) 14.58 (12.99) 14.29 (11.69) 15 25.20 (13.77) 16.66 (11.57) 20.60 (15.89) 20.337nnn .155 3.675n
WHOQOL 22 78.59 (9.00) 85.95 (15.40) 88.31 (15.71) 15 80.33 (14.65) 86.07 (13.02) 85.93 (14.89) 11.230nnn .002 .708
Process
AAQ 22 4.84 (.85) 3.98 (1.11) 3.93 (.98) 13 4.47 (.82) 4.26 (.74) 4.44 (.95) 7.551nnn .165 4.103n
MAAS 23 51.52 (9.32) 60.56 (10.58) 60.60 (13.88) 16 52.56 (16.09) 56.62 (12.02) 60.12 (14.51) 9.109nnn .112 .771
ATQ-TB 22 94.45 (26.65) 75.13 (33.75) 66.90 (35.23) 16 93.56 (35.83) 76.06 (29.07) 82.81 (34.53) 6.179nn .441 1.115
ATQ-TF 22 92.59 (28.42) 67.13 (26.91) 62.72 (30.66) 16 91.50 (34.38) 69.94 (23.64) 69.12 (28.34) 17.581nnn .125 .298
Note: BDI-II, Beck's Depression Inventory; GSI, Global Severity Index; WHOQOL, Quality of Life; AAQ, Acceptance and Action Questionnaire; MAAS, Mindfulness Attention and
Awareness Scale; ATQ-TB, Automatic Thoughts Questionnaire – Thought Believability; ATQ-TF, Automatic Thoughts Questionnaire – Thought Frequency; BASELINE, Baseline;
POST-THERAPY, Post-treatment; FOLLOW-UP, 6-month follow-up.
n Po .05.
nn Po .01.
nnn Po .001.
Fig. 2. Changes in mean BDI-II and GSI scores (with SE bars) across testing periods for both groups. ACT, acceptance commitment therapy, TAU-CBT, treatment-as-usual
based on cognitive behavioural therapy.
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again apparent for all outcome measures (GSI: F(2, 118)¼13.782,
p¼o .001; BDI-II: F(2, 112)¼24.991, po .001; and WHOQOL: F(2,
118)¼17.012, po .001). Post hoc pairwise comparisons revealed
signiﬁcant reductions in GSI scores from baseline to post-therapy
(F(1, 60)¼11.526, po .001) and baseline to follow-up (F(1, 60)¼
17.172, po .001). BDI-II scores signiﬁcantly improved from baseline
to post-therapy (F(1, 58)¼34.056, po .001) and baseline to follow-
up (F(1, 57)¼25.506, po .001). WHOQOL scores signiﬁcantly
improved from baseline to post-therapy (F(1, 60)¼21.191, po
.001) and baseline to follow-up (F(1, 60)¼21.755, po .001).
The BDI-II GroupTime interaction approached signiﬁcance
(F(1, 59)¼3.324, p¼ .073) and post hoc analysis showed the same
pattern as that observed for the treatment completers. Signiﬁcant
baseline to post-therapy reductions in BDI-II occurred for both
groups (ACT: F(1, 28)¼28.114, po .001; CBT: F(1, 29)¼9.394,
p¼ .005) but change from baseline to follow-up was signiﬁcant
only for the ACT group (ACT: F(1, 28)¼25.122, po .001; TAU-CBT:
F(1, 28)¼4.790, p¼ .037). Because broadly similar outcomes were
obtained from treatment-completers and intention-to-treat ana-
lyses, subsequent discussion will rely on the latter.
3.5. Clinically signiﬁcant individual change
Norms used for change calculations were drawn from pub-
lished psychometric data (Beck et al., 1996b; Derogatis, 1993;
Dozois, Dobson, & Ahnberg, 1998). Based on the recommendations
of Thomas and Truax (2008), the following categories of change
were calculated: recovered (reliable and signiﬁcant clinical
change), improved (reliable change, without signiﬁcant clinical
change), same (no change) and deteriorated (reliable change in
direction of worsening symptoms). Next, Chi-square analyses
comparing “Recovered or Improved” and “Same or Deteriorated”
participants were computed to compare individual patterns of
change between conditions. The percentage of ACT and TAU-CBT
participants, who reliably recovered, improved, remained the
same or deteriorated at post-therapy and follow-up is shown in
Table 3. These analyses suggest that, in comparison with TAU-CBT
participants, a signiﬁcantly greater number of ACT participants
made reliable and clinically signiﬁcant improvements according to
scores on the GSI and BDI-II at both post-therapy (respectively,
χ²¼4.471, p¼ .034; χ²¼4.127, p¼ .042) and follow-up (respectively,
χ²¼7.412, p¼ .006; χ²¼7.519, p¼ .006).
3.6. Process variables
Based on ACT theory, we expected that ACT would reduce AAQ
and ATQ-TB and increase MAAS scores. For the TAU-CBT, only a
reduction in ATQ-TF was anticipated.
A mixed-design ANOVA (see Table 2) showed a signiﬁcant
effect of time for all process measures, with post hoc analyses
indicating a signiﬁcant baseline to post-therapy reduction in AAQ
(F(1, 34)¼9.725, p¼ .004), MAAS scores (F(1, 38)¼13.413, p¼ .001),
ATQ-TB (F(1, 38)¼8.351, p¼ .006) and ATQ-TF (F(1, 38)¼28.430,
po .001). From baseline to follow-up, the pattern was the same:
AAQ (F(1, 36)¼11.770, p¼ .002), MAAS (F(1, 41)¼10.733, p¼ .002),
ATQ-TB (F(1, 40)¼11.983, p¼ .001) and ATQ-TF (F(1, 40)¼24.516,
po .001). Although between-group differences were not signiﬁ-
cant, a GroupTime interaction was observed for the AAQ, with
post hoc analyses revealing signiﬁcant baseline to post-therapy
and baseline to follow-up reductions for the ACT group (respec-
tively, F(1, 21)¼11.979, p¼ .002; F(1, 22)¼13.563, p¼ .001) but not
for the TAU-CBT.
Given the differential changes in AAQ scores between baseline
and post-therapy time points, multiple regressions were com-
puted to test whether these changes were associated only with
follow-up outcomes for the ACT group but not the TAU-CBT group.
In the ACT group, AAQ residual gain pre-post scores were sig-
niﬁcantly predictive of both GSI and BDI-II at follow-up (respec-
tively, β¼ .615, p¼ .001; β¼ .599, p¼ .003) and approached, but did
not reach signiﬁcance for, follow-up WHOQOL (β¼ .293, p¼ .057)
scores. For the TAU-CBT group, AAQ residual gain scores were not
signiﬁcantly related to any outcome measures at follow-up.
Multiple regression analyses were also computed to test
whether baseline to post-intervention changes in ATQ-TB scores
were associated with follow-up outcomes for the ACT group, but
not CBT group. In keeping with our expectation, the ACT group,
ATQ-TB residual gain scores were signiﬁcantly predictive of GSI
and BDI-II at follow-up (respectively, β¼ .490, p¼ .020; β¼ .506,
p¼ .022). However, ATQ-TB residual gain scores were not predic-
tive of WHOQOL at follow-up. For the TAU-CBT group, ATQ-TB
residual gain scores were not related to any follow-up outcome
measures. Contrary to our expectation, ATQ-TF residual gain scores
were not signiﬁcantly predictive of outcome in the TAU-CBT group,
but they were in the ACT group. Speciﬁcally, ATQ-TF residual gain
scores were signiﬁcantly predictive of GSI and BDI-II at follow-up
(GSI: β¼ .737, po .001; BDI-II: β¼ .570, p¼ .007), and approached,
but did not reach signiﬁcance for, WHOQOL scores (β¼ .287,
p¼ .070).
Finally, to assess for dormant effects of previous therapies, non-
parametric correlations were used to assess the relationship
between the previous number of therapeutic sessions and pre-
post change in outcome measures. These correlations were not
signiﬁcant (all p4 .05).
4. Discussion
Our results indicate that group-based intervention for a hetero-
geneous group of treatment-resistant participants produced sub-
stantial improvements. Group analyses showed that mean levels
of deleterious psychological symptoms and baseline depression
were signiﬁcantly reduced after intervention and at follow-up, and
quality of life improved, regardless of whether participants
received ACT or TAU-CBT. A similar pattern of results also emerged
from more conservative intention-to-treat analyses. There was no
relationship between the previous number of therapeutic sessions
and pre-post change in outcome measures, suggesting that
improvements were unlikely to be related to the dormant effects
of previous therapies.
Although no main effects of therapy (group) on depressive
symptoms were observed, Group Time interaction effects and
effect size analyses indicated that the improvements following
ACT exceeded those for TAU-CBT. Within-group post hoc analyses
showed that, unlike TAU-CBT participants, ACT participants con-
tinued to show signiﬁcantly reduced depression at 6-month
Table 3
Percentage of reliable and clinically signiﬁcant change for both conditions.
GSI BDI-II
Post-therapyn Follow-upnn Post-therapyn Follow-upnn
ACT TAU-
CBT
ACT TAU-
CBT
ACT TAU-
CBT
ACT TAU-
CBT
Recovered (%) 32 6 44 12 58 13 58 6
Improved (%) 12 6 16 6 8 20 17 25
Same (%) 48 81 36 76 33 60 25 63
Deteriorated
(%)
8 6 4 6 0 7 0 6
Note: GSI, Global Severity Index; BDI-II, Beck's Depression Inventory.
n Po .05.
nn Po .01.
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follow-up, with large effect sizes favoring ACT. Similarly, despite
the absence of signiﬁcant Group Time interactions, medium and
small effect sizes in favor of ACT were observed for reductions of
overall psychological symptoms and quality of life at 6-month
follow-up.
Group analyses were supported by assessment of changes on
an individual basis, both immediately post-therapy and at follow-
up. In each case, a signiﬁcantly greater proportion of ACT partici-
pants were classiﬁed as “recovered” or “improved” on primary
outcome measures; in contrast, a signiﬁcantly greater proportion
of TAU-CBT participants were categorized as the “same” or
“deteriorated”.
Overall, these ﬁndings suggest that participants who received
ACT maintained their post-treatment gains on primary outcome
measures (GSI; BDI-II) at follow-up, whereas those who received
TAU-CBT showed weaker maintenance. These outcomes parallel
the results of previous ACT research (Clarke et al., 2012; Gifford et
al., 2004; Hayes et al., 2004b; Lundgren, Dahl, Melin, & Kies, 2006)
suggesting an “incubation effect”, whereby improvement is main-
tained after ACT treatment ceases. Hollon, Stewart, and Strunk
(2006) distinguish between interventions that produce palliative
effects that “suppress the expression of the disorder so long as
they are applied” (p. 287) and those that are enduring and curative
(i.e., those that “reverse(d) processes that would otherwise lead to
the continuation of the disorder”; p. 287). ACT may achieve
enduring effects because interventions focus on increasing psy-
chological ﬂexibility in the service of engaging in more valued,
meaningful activities, even if these may occasionally expose clients
to aversive experiences. To the extent that exposure is a useful
therapeutic tool, behaviors that produce repeated self-initiated
exposure might be expected to produce continuing gains. This
interpretation is supported by the AAQ process data. These
showed that, for the ACT group alone, residual gains at post-test
were signiﬁcantly predictive of improved GSI and BDI-II scores at
follow-up.
Our data support the view that the core theoretical principles
of ACT can be applied across diagnoses, suggesting ACT may be a
second-line approach for individuals who have not beneﬁtted
from previous ﬁrst-line interventions, including CBT. Moreover,
the application of ACT as a group-based approach also has practical
and economic implications for service delivery.
Using an RCT design in a naturalistic setting created some
tensions between research and practice which contributed to both
the strengths and limitations of the study. For example, both
interventions were consistent with clinical practice in the real
world public sector service providing treatment to a heteroge-
neous group of “treatment-resistant” clients. Such clients, highly
prevalent in clinical practice (Fournier et al., 2008), are sometimes
excluded from outcome research (Persons & Silberschatz, 1998;
Westen et al., 2004; Zarin et al., 2005). The ecological validity of
the study was, however, limited because clients displaying risky
behavior were excluded, so the sample may not be fully repre-
sentative of the treatment-resistant population.
Although in keeping with previous ACT research in terms of
methodology, a signiﬁcant limitation of the study was its relatively
small sample size, and the fact that markedly more participants
dropped out from TAU-CBT than ACT. This differential attrition
may, however, be of some clinical signiﬁcance. Perhaps ACT is
more acceptable to treatment-resistant clients either because of its
novelty and/or previous unsuccessful experiences with CBT-based
interventions. In future research, it would be possible to test these
admittedly post hoc hypotheses using structured interviews to
follow-up participants who dropped out. A second concern is that
differential attrition may have affected our comparisons. Fortu-
nately, however, intention-to-treat analyses produced ﬁndings
that were broadly in line with the treatment-completers analyses.
Although non-treatment speciﬁc factors—such as therapeutic
alliance or quality of supervision—were not assessed and may
have contributed to change, most therapeutic time was spent
on treatment-speciﬁc components. Moreover, most rated sessions
(79%) were judged “good” to “excellent” and there was no differ-
ence between the two conditions on the relationship-building
subscale of the DUACRS.
Finally, the SCID measure was rated by assessors who were not
blind to group assignment, but there was good inter-rater relia-
bility with second raters naïve to treatment allocation. All other
key measures were self-report questionnaires completed privately
by participants.
In conclusion, our ﬁndings provide evidence that group-based
ACT is more effective than CBT-based TAU in maintaining out-
comes for a group of treatment-resistant participants experiencing
a range of heterogeneous difﬁculties. ACT may also be more
acceptable to treatment-resistant participants, possibly by virtue
of their previous experiences of CBT. Future research building on
these ﬁndings would beneﬁt from a fully powered evaluation of
ACT for treatment-resistant participants, again in comparison with
an evidence-based intervention. Given the increased potential for
relapse amongst treatment-resistant participants, longer-term fol-
low-ups (e.g., 12- or 18-months) would be valuable. Such compar-
isons would also beneﬁt from a formal assessment of process
variables and a cost-effectiveness evaluation.
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